Related Experiment Videos
Acute leukemia during pregnancy: a single institutional experience with 17 cases
L J Greenlund1, L Letendre, A Tefferi
1Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
Leukemia & Lymphoma
|May 30, 2001
Summary
Pregnancy does not appear to negatively impact chemotherapy outcomes for acute myeloid leukemia (AML). Delaying treatment for AML during pregnancy may worsen maternal survival without improving pregnancy outcomes.
Area of Science:
- Oncology
- Hematology
- Maternal-Fetal Medicine
Background:
- Concomitant acute leukemia and pregnancy presents unique management challenges.
- Acute myeloid leukemia (AML) is a critical diagnosis that requires timely intervention.
Purpose of the Study:
- To evaluate the impact of pregnancy on chemotherapy outcomes in patients with acute myeloid leukemia (AML).
- To assess the safety and efficacy of AML treatment during pregnancy.
Main Methods:
- Retrospective review of medical records for 17 patients with acute leukemia and pregnancy over 37 years.
- Analysis of treatment timing, chemotherapy regimens, remission rates, survival, and pregnancy outcomes.
Main Results:
- Fifteen patients had acute myeloid leukemia (AML), with diagnoses across all trimesters.
- Chemotherapy during pregnancy (n=9) showed a high complete remission rate (86%) in newly diagnosed AML patients.
- Delayed treatment post-delivery was associated with poor maternal survival; no congenital malformations were observed.
Conclusions:
- Pregnancy itself does not adversely affect chemotherapy outcomes in AML.
- Treatment delays for AML during pregnancy may compromise maternal survival without benefiting pregnancy outcomes.